Skip to content
Contact
NexaBiome Life Sciences

Harnessing the power of nature to tackle the AMR crisis.

Antimicrobial resistance (AMR) is one of the greatest threats to modern medicine, turning once-routine infections into potentially deadly diseases.

NexaBiome Life Sciences is developing products based on natural antimicrobials (bacteriophages or phages) to treat drug-resistant bacterial infections.

3D illustration of bacteriophages attaching to a bacterium
10 million

people a year could die due to AMR by 2050

$1 trillion

cumulative cost of AMR to the global economy

1.9 million

deaths directly attributable to AMR in 2025

1031

phages on the planet, outnumbering all other cellular life combined

The problem

Antimicrobial resistance

Antimicrobial resistance (AMR) is putting modern medicine at risk. As infections become harder to treat, healthcare systems worldwide need new antimicrobial approaches.

Find out more

A gloved hand holding a petri dish used for antimicrobial susceptibility testing
3D illustration of bacteriophages infecting a bacterium
The solution

Bacteriophages

Bacteriophages, or phages, are natural bacterial killers. They offer a fundamentally different way to target bacterial infections.

Find out more

Our technology

Our Technology

NexaBiome Life Sciences is developing technologies that overcome key barriers that have limited phage development, helping turn phages into practical antimicrobial products.

Find out more

Plasma glowing inside a vacuum chamber
Our focus

Targeting an urgent unmet need

Two footprints pressed into white sugar
The target

Diabetic foot infections

A common and serious complication of diabetes. DFIs can have life-changing consequences for patients and place significant pressure on healthcare systems worldwide.

Find out more : Diabetic foot infections
Gauze pads and a wound dressing on a blue surface
The product

A phage wound dressing

NexaBiome Life Sciences is using its patented technology to develop a wound dressing that targets Staphylococcus aureus, a key pathogen in diabetic foot infections.

Find out more : A phage wound dressing
Investors

A sustainable antimicrobial business

Combining an urgent unmet need with differentiated technology and a commercially focused development strategy.

Explore the opportunity